1 Min Read
Jan 22 (Reuters) - Carmat SA :
* Will benefit from the European Seed1 program that supports therapy developers seeking reimbursement Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.